Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | PKM | P14618 | 1/20 | 0.50 |
| ▸ | TSHR | P16473 | 1/20 | 0.50 |
| ▸ | RAB9A | P51151 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | CDK5 | Q00535 | 2/20 | 0.47 |
| ▸ | CDK5R1 | Q15078 | 2/20 | 0.47 |
| ▸ | KCNQ3 | O43525 | 2/20 | 0.46 |
| ▸ | KCNQ2 | O43526 | 2/20 | 0.46 |
| ▸ | KCNQ5 | Q9NR82 | 1/20 | 0.46 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.45 |
| ▸ | PARP1 | P09874 | 1/20 | 0.45 |
| ▸ | MAP4K4 | O95819 | 2/20 | 0.44 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.44 |
| ▸ | KCNE1 | P15382 | 1/20 | 0.44 |
| ▸ | KCNQ1 | P51787 | 1/20 | 0.44 |
| ▸ | CHRNA7 | P36544 | 4/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | CES2 | O00748 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28239 | 0.84 | CHRNA7 (0.48) | ALDH1A1MAP4K4MAPK14CHRNA7 | |
| SCHEMBL3201326 | 0.84 | PARP1 (0.50) | NPC1ALDH1A1PKMTSHRRAB9A | |
| SCHEMBL305753 | 0.81 | NPC1 (0.50) | NPC1ALDH1A1PKMTSHRRAB9A | |
| SCHEMBL2705329 | 0.80 | RECQL (0.54) | NPC1ALDH1A1PKMTSHRRAB9A | |
| SCHEMBL27804 | 0.77 | CHRNA7 (0.47) | RAB9ASMN1; SMN2CHEK2MAP4K4CHRNA7 | |
| SCHEMBL8956721 | 0.75 | PARP1 (0.49) | NPC1ALDH1A1PKMTSHRRAB9A | |
| SCHEMBL14419278 | 0.74 | KMT2A (0.50) | NPC1ALDH1A1PKMTSHRRAB9A | |
| SCHEMBL4997555 | 0.73 | KCNQ3 (0.53) | NPC1ALDH1A1PKMTSHRRAB9A | |
| SCHEMBL4960341 | 0.72 | USP2 (0.52) | NPC1ALDH1A1PKMTSHRRAB9A | |
| SCHEMBL14415722 | 0.72 | CES2 (0.59) | NPC1ALDH1A1PKMTSHRRAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160068479-A1 | CCR9 INHIBITORS AND METHODS OF USE THEREOF | MILLENNIUM PHARMECEUTICALS INC (US) | 2016-03-10 | — | — | US | disclosed |
| EP-1507756-B1 | CCR9 INHIBITORS AND METHODS OF USE THEREOF | MILLENNIUM PHARM INC (US) | 2015-07-22 | — | — | EP | disclosed |
| US-9035096-B2 | CCR9 inhibitors and methods of use thereof | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2015-05-19 | — | — | US | disclosed |
| US-20140107160-A1 | CCR9 INHIBITORS AND METHODS OF USE THEREOF | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2014-04-17 | — | — | US | disclosed |
| US-8569543-B2 | CCR9 inhibitors and methods of use thereof | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2013-10-29 | — | — | US | disclosed |
| US-20110313000-A1 | CCR9 INHIBITORS AND METHODS OF USE THEREOF | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2011-12-22 | — | — | US | disclosed |
| US-20100324093-A1 | CCR9 INHIBITORS AND METHODS OF USE THEREOF | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2010-12-23 | — | — | US | disclosed |
| US-20100280074-A1 | CCR9 INHIBITORS AND METHODS OF USE THEREOF | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2010-11-04 | — | — | US | disclosed |
| US-7820717-B2 | CCR9 inhibitors and methods of use thereof | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2010-10-26 | — | — | US | disclosed |
| US-20100093802-A1 | CCR9 INHIBITORS AND METHODS OF USE THEREOF | MILLENNNIUM PHARMACEUTICALS, INC. (US) | 2010-04-15 | — | — | US | disclosed |
| US-7659272-B2 | CCR9 inhibitors and methods of use thereof | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2010-02-09 | — | — | US | disclosed |
| US-20090054495-A1 | CCR9 inhibitors and methods of use thereof | MILLENNIUM PHARMACEUTICALS, INC. | 2009-02-26 | — | — | US | disclosed |
| US-20080103180-A1 | CCR9 inhibitors and methods of use thereof | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2008-05-01 | — | — | US | disclosed |
| US-7282502-B2 | CCR9 inhibitors and methods of use thereof | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2007-10-16 | — | — | US | disclosed |
| US-7238717-B2 | CCR9 inhibitors and methods of use thereof | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2007-07-03 | — | — | US | disclosed |
| US-20070066823-A1 | CCR9 inhibitors and methods of use thereof | MILLENNIUM PHARMACEUTICALS, INC. | 2007-03-22 | — | — | US | disclosed |
| US-20070021466-A1 | CCR2 inhibitors and methods of use thereof | CHEMOCENTRYX, INC. | 2007-01-25 | — | — | US | disclosed |
| US-20060167251-A1 | CCR9 inhibitors and methods of use thereof | MILLENNIUM PHARMACEUTICALS, INC. | 2006-07-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070021466-A1 | CCR2 inhibitors and methods of use thereof | CCR2, CCR1, CCL2 | NPC1 1045/4885ALDH1A1 1582/4885PKM 3340/4885 |
| US-20110313000-A1 | CCR9 INHIBITORS AND METHODS OF USE THEREOF | CCR9, CCR1, CCR4 | NPC1 782/4885ALDH1A1 2607/4885PKM 3823/4885 |
| US-20100093802-A1 | CCR9 INHIBITORS AND METHODS OF USE THEREOF | CCR9, CCR1, CCR4 | NPC1 782/4885ALDH1A1 2607/4885PKM 3823/4885 |
| US-20060167251-A1 | CCR9 inhibitors and methods of use thereof | CCR9, CCR1, CCR4 | NPC1 782/4885ALDH1A1 2607/4885PKM 3823/4885 |
| US-20100280074-A1 | CCR9 INHIBITORS AND METHODS OF USE THEREOF | CCR9, CCR1, CCR4 | NPC1 782/4885ALDH1A1 2607/4885PKM 3823/4885 |
| US-20140107160-A1 | CCR9 INHIBITORS AND METHODS OF USE THEREOF | CCR9, CCR1, CCR4 | NPC1 782/4885ALDH1A1 2607/4885PKM 3823/4885 |
| US-20160068479-A1 | CCR9 INHIBITORS AND METHODS OF USE THEREOF | CCR9, CCR1, CCR4 | NPC1 782/4885ALDH1A1 2607/4885PKM 3823/4885 |
| US-20090054495-A1 | CCR9 inhibitors and methods of use thereof | CCR9, CCR1, CCR4 | NPC1 782/4885ALDH1A1 2607/4885PKM 3823/4885 |
| US-20070066823-A1 | CCR9 inhibitors and methods of use thereof | CCR9, CCR1, CCR4 | NPC1 782/4885ALDH1A1 2607/4885PKM 3823/4885 |
| US-20100324093-A1 | CCR9 INHIBITORS AND METHODS OF USE THEREOF | CCR9, CCR1, CCR4 | NPC1 782/4885ALDH1A1 2607/4885PKM 3823/4885 |
| US-20080103180-A1 | CCR9 inhibitors and methods of use thereof | CCR9, CCR1, CCR4 | NPC1 782/4885ALDH1A1 2607/4885PKM 3823/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.